Table 2.

Overview of included studies with patient characteristics, complication rates, response assessment and survival (in months).

Author(s) (year)	Study design	Number of patients	Treatment	Population characteristics	Grade NET	Complication rate	Response
Soulen et al. (2024)	Single-center prospective/retrospective study	n = 37	Radioembolization with 90Y resin + CapTem	Primary tumor - Pancreas 43% - Gut 19% - Other 38%	- 2 (100%)	- REILD NR - Ulcera NR - Radiation pneumonitis NR - Radiation pancreatitis NR - Radiation cholecystitis NR	ORR 72% PFS 36 OS 41
Schaarschmidt et al. (2022)	Multicenter retrospective study	n = 297	Radioembolization with 90Y glass or resin	Primary tumor - Pancreas 24.9% - Small bowel 31.1% - Other 44%	- 1 (25.6%) - 2 (50.5%) - 3 (5.7%) - Unknown (9.1%)	- REILD NR - Ulcera NR - Radiation pneumonitis NR - Radiation pancreatitis NR - Radiation cholecystitis NR	ORR 41.3% PFS 15.9 OS 30.6
Wong et al. (2022)	Multicenter retrospective study	n = 170	Radioembolization with 90Y resin	Primary tumor - Pancreas 24% - Midgut 36% - Other 40%	- 1 (70%) - 2 (15%) - 3 (15%)	- REILD NR - Ulcera NR - Radiation pneumonitis NR - Radiation pancreatitis NR - Radiation cholecystitis NR	ORR 36% PFS 25 OS 33
Braat et al. (2020)	Single-center prospective study	n = 34	Radioembolization with 166Ho	Primary tumor - Pancreas (32%) - Ileum or jejunum (29%) - Other (39%)	- 1 (35%) - 2 (65%)	- REILD 3% - Ulcera 0% - Radiation pneumonitis 0% - Radiation pancreatitis 0% - Radiation cholecystitis 0%	ORR 60% PFS NR OS NR
Braat et al. (2019)	Multicenter retrospective study	n = 244	Radioembolization with 90Y resin	Primary tumor - Pancreas 31.2% - Small bowel 34.9% - Other 33.9%	- 1 (39.3%) - 2 (35.7%) - 3 (10.2%) - Unknown (14.8%)	- REILD 0.8% - Ulcera 2.8% - Radiation pneumonitis 0.4% - Radiation pancreatitis 0% - Radiation cholecystitis 0%	ORR 15.7% PFS NR OS 31.2
Chen et al. (2017)	Multicenter retrospective study	n = 155	Radioembolization with 90Y resin or glass	Primary tumor - Pancreas 40% - Gastrointestinal 47% - Other 13%	- 1 (50%) - 2 (39%) - 3 (11%)	- REILD 4.5% - Ulcera 0.006% - Radiation pneumonitis NR - Radiation pancreatitis NR - Radiation cholecystitis NR	ORR NR PFS 15.7 OS 48.2
Kennedy et al. (2008)	Multicenter retrospective study	n = 148	Radioembolization with 90Y resin	Primary tumor - Pancreas 19% - Small intestine 67% - Other 14%	NR	- REILD 0% - Ulcera NR - Radiation pneumonitis NR - Radiation pancreatitis NR - Radiation cholecystitis NR	ORR 63.2% PFS NR OS NR

Abbreviations: ⁹⁰Y, yttrium-90; CTCAE, Common Terminology Criteria for Adverse Events; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; NR, not reported.